SuperworthCingulate market cap CING
Share price times shares outstanding: what the whole company sells for, since 2022.
- Today, Oct 23, 2026
- $72.4M
- Highest close in our data
- $85.8M
- Mar 2026
Cingulate is worth $72.4M at the close on Oct 23, 2026, at $4.98 a share.
That is up 247% over the last year and up 246% over five years.
Its highest close in our data was $85.8M in Mar 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $72.4M | $29.6M | $85.8M | +156% |
| 2025 | $28.2M | $11.5M | $30M | +84% |
| 2024 | $15.4M | $974.5K | $16.8M | +114% |
| 2023 | $7.2M | $1.9M | $20.9M | −37% |
| 2022 | $11.3M | $10M | $21M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Cingulate's size, closest first, today.
| Company | Market cap |
|---|---|
| CINGCingulate | $72.4M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| Peer median | $477.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Cingulate
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.